{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:16:15Z","timestamp":1793301375081,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Japan Agency for Medical Research and Development","id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.omtn.2019.07.018","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T20:10:16Z","timestamp":1564690216000},"page":"819-828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease"],"prefix":"10.1016","volume":"17","author":[{"given":"Yusaku","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Futakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Akita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Nishihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Bhisitkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8763-0424","authenticated-orcid":false,"given":"Yoshikazu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2019.07.018_bib1","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.15-17681","article-title":"Stem cell therapy in nonneovascular age-related macular degeneration","volume":"57","author":"Kashani","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtn.2019.07.018_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4097","article-title":"A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration","volume":"10","author":"Kashani","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2019.07.018_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2015.04.003","article-title":"Incidence of late-stage age-related macular degeneration in American whites: systematic review and meta-analysis","volume":"160","author":"Rudnicka","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtn.2019.07.018_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ajo.2011.02.004","article-title":"Racial differences in age-related macular degeneration rates in the United States: a longitudinal analysis of a managed care network","volume":"152","author":"Vanderbeek","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtn.2019.07.018_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0002-9440(10)65138-3","article-title":"Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation","volume":"155","author":"Blaauwgeers","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2019.07.018_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1089\/nat.2015.0573","article-title":"Fit for the eye: aptamers in ocular disorders","volume":"26","author":"Drolet","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2019.07.018_bib7","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2019.07.018_bib8","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtn.2019.07.018_bib9","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtn.2019.07.018_bib10","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtn.2019.07.018_bib11","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ophtha.2016.01.033","article-title":"Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study)","volume":"123","author":"Bhisitkul","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtn.2019.07.018_bib12","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtn.2019.07.018_bib13","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of scar in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtn.2019.07.018_bib14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1172\/JCI31030","article-title":"Fibrosis and diseases of the eye","volume":"117","author":"Friedlander","year":"2007","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtn.2019.07.018_bib15","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials","volume":"120","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtn.2019.07.018_bib16","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archopht.1988.01060140705039","article-title":"Natural course of poorly defined choroidal neovascularization associated with macular degeneration","volume":"106","author":"Bressler","year":"1988","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.omtn.2019.07.018_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.omtn.2019.07.018_bib18","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/00006982-200512000-00016","article-title":"neovascular age-related macular degeneration: Natural History and Treatment Outcomes","volume":"25","author":"Pauleikhoff","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.omtn.2019.07.018_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.eye.6701787","article-title":"Does lesion size determine the success rate of photodynamic therapy for age-related macular degeneration?","volume":"20","author":"Sivaprasad","year":"2006","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.omtn.2019.07.018_bib20","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/IAE.0b013e318240a516","article-title":"Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings","volume":"32","author":"Cohen","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.omtn.2019.07.018_bib21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/eye.1991.31","article-title":"Neovascular growth factors","volume":"5","author":"Schultz","year":"1991","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.omtn.2019.07.018_bib22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1755-3768.1990.tb01668.x","article-title":"Occurrence of drusen, pigmentary changes and exudative changes in the macula with reference to age-related macular degeneration. An epidemiological study of 1000 aged individuals","volume":"68","author":"Vinding","year":"1990","journal-title":"Acta Ophthalmol. (Copenh.)"},{"key":"10.1016\/j.omtn.2019.07.018_bib23","first-page":"26","article-title":"Biological roles of fibroblast growth factor-2","volume":"18","author":"Bikfalvi","year":"1997","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.omtn.2019.07.018_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cytogfr.2005.01.004","article-title":"Fibroblast growth factor\/fibroblast growth factor receptor system in angiogenesis","volume":"16","author":"Presta","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.omtn.2019.07.018_bib25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2019.07.018_bib26","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hh1101.091191","article-title":"Vascular endothelial growth factor and basic fibroblast growth factor differentially modulate early postnatal coronary angiogenesis","volume":"88","author":"Tomanek","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.omtn.2019.07.018_bib27","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1046\/j.1365-2362.2003.01223.x","article-title":"Basic fibroblast growth factor induces the secretion of vascular endothelial growth factor by human aortic smooth muscle cells but not by endothelial cells","volume":"33","author":"Belgore","year":"2003","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.omtn.2019.07.018_bib28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/CIRCRESAHA.107.168682","article-title":"Activation transcription factor-4 induced by fibroblast growth factor-2 regulates vascular endothelial growth factor-A transcription in vascular smooth muscle cells and mediates intimal thickening in rat arteries following balloon injury","volume":"103","author":"Malabanan","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.omtn.2019.07.018_bib29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nm848","article-title":"Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2","volume":"9","author":"Cao","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2019.07.018_bib30","article-title":"The corneal micropocket assay: a model of angiogenesis in the mouse eye","volume":"90","author":"Birsner","year":"2014","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.omtn.2019.07.018_bib31","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1046\/j.1523-1755.2002.00333.x","article-title":"Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation","volume":"61","author":"Strutz","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.omtn.2019.07.018_bib32","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/jcp.24610","article-title":"TGF-\u03b21 and FGF2 stimulate the epithelial-mesenchymal transition of HERS cells through a MEK-dependent mechanism","volume":"229","author":"Chen","year":"2014","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.omtn.2019.07.018_bib33","first-page":"1975","article-title":"Transforming growth factor-beta1, -beta2, and -beta3 in\u00a0vivo: effects on normal and mitomycin C-modulated conjunctival scarring","volume":"40","author":"Cordeiro","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtn.2019.07.018_bib34","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00417-011-1730-9","article-title":"The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR)","volume":"249","author":"Nassar","year":"2011","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.omtn.2019.07.018_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.gt.3301865","article-title":"Novel antisense oligonucleotides targeting TGF-beta inhibit in\u00a0vivo scarring and improve surgical outcome","volume":"10","author":"Cordeiro","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2019.07.018_bib36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1096\/fj.13-229740","article-title":"Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy","volume":"28","author":"Ishikawa","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.omtn.2019.07.018_bib37","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/mt.2016.158","article-title":"Dual therapeutic action of a neutralizing anti-FGF2 aptamer in bone disease and bone cancer pain","volume":"24","author":"Jin","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2019.07.018_bib38","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In\u00a0vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2019.07.018_bib39","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.omtn.2019.07.018_bib40","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4049\/jimmunol.168.1.450","article-title":"Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats","volume":"168","author":"Yamashita","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2019.07.018_bib41","doi-asserted-by":"crossref","first-page":"9911","DOI":"10.1073\/pnas.86.24.9911","article-title":"Monoclonal antibodies against heparin-binding growth factor II\/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis","volume":"86","author":"Matsuzaki","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2019.07.018_bib42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/08977199909002126","article-title":"Development of novel monoclonal antibodies for the analysis of functional sites in FGF-2","volume":"16","author":"Rege","year":"1999","journal-title":"Growth Factors"},{"key":"10.1016\/j.omtn.2019.07.018_bib43","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1158\/1535-7163.MCT-11-0813","article-title":"A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts","volume":"11","author":"Wang","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omtn.2019.07.018_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.02.2012.5942","article-title":"Intravitreal dobesilate in the treatment of choroidal neovascularisation associated with age-related macular degeneration: report of two cases","volume":"2012","author":"Cuevas","year":"2012","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.omtn.2019.07.018_bib45","article-title":"Treatment of Stargardt disease with dobesilate","volume":"2012","author":"Cuevas","year":"2012","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.omtn.2019.07.018_bib46","article-title":"Chronic cystoid macular oedema treated with intravitreal dobesilate","volume":"2012","author":"Cuevas","year":"2012","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.omtn.2019.07.018_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.02.2012.5942","article-title":"Treatment of dry age-related macular degeneration with dobesilate","volume":"2012","author":"Cuevas","year":"2012","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.omtn.2019.07.018_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2047-783X-17-22","article-title":"Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy","volume":"17","author":"Cuevas","year":"2012","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.omtn.2019.07.018_bib49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4236\/jbise.2013.610A2002","article-title":"Dobesilate for dry age-related macular degeneration","volume":"6","author":"Cuevas","year":"2013","journal-title":"J.\u00a0Biomed. Sci. Eng."},{"key":"10.1016\/j.omtn.2019.07.018_bib50","first-page":"3178","article-title":"Growth factor localization in choroidal neovascular membranes of age-related macular degeneration","volume":"35","author":"Amin","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtn.2019.07.018_bib51","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0002-9394(14)72066-5","article-title":"Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes","volume":"122","author":"Frank","year":"1996","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtn.2019.07.018_bib52","doi-asserted-by":"crossref","first-page":"13379","DOI":"10.1073\/pnas.1324235111","article-title":"Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis","volume":"111","author":"Oladipupo","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2019.07.018_bib53","unstructured":"ClinicalTrials.gov. RBM-007 in Subjects with Exudative Age-related Macular Degeneration (SUSHI). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03633084."},{"key":"10.1016\/j.omtn.2019.07.018_bib54","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1167\/iovs.07-1194","article-title":"Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes","volume":"49","author":"Campa","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtn.2019.07.018_bib55","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1007\/s11095-004-7676-4","article-title":"Pharmacokinetics and biodistribution of novel aptamer compositions","volume":"21","author":"Healy","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.omtn.2019.07.018_bib56","doi-asserted-by":"crossref","unstructured":"U.S. Food and Drug Administration. Drug Approval Package: Macugen (Pegaptanib Sodium) Injection.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/21-756_Macugen.cfm.","DOI":"10.3833\/pdr.v2004i54.746"},{"key":"10.1016\/j.omtn.2019.07.018_bib57","unstructured":"U.S. Food and Drug Administration. Drug Approval Package: Lucentis (Ranibizumab) Injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/125156s0000_LucentisTOC.cfm."},{"key":"10.1016\/j.omtn.2019.07.018_bib58","unstructured":"U.S. Food and Drug Administration. Drug Approval Package: Eylea (Aflibercept)\u00a0Injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/125387s0000TOC.cfm."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253119302082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253119302082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T12:22:51Z","timestamp":1721564571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253119302082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":58,"alternative-id":["S2162253119302082"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2019.07.018","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2019.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}